GTX Inc /De/ Sample Contracts

COMMON STOCK PURCHASE WARRANT ONCTERNAL THERAPEUTICS, INC.
Oncternal Therapeutics, Inc. • May 21st, 2020 • Pharmaceutical preparations

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on November 21, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

AutoNDA by SimpleDocs
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • May 21st, 2020 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of May 19, 2020, between Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

UNDERWRITER COMMON STOCK PURCHASE WARRANT ONCTERNAL THERAPEUTICS, INC.
Oncternal Therapeutics, Inc. • December 11th, 2020 • Pharmaceutical preparations • New York

THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on December 9, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock, as defined in Section 1 herein. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to the Underwriting Agreement, as defined in Section 1 herein.

L E A S E
GTX Inc/Tn • October 15th, 2003
GTX, INC. COMMON STOCK (PAR VALUE $0.001 PER SHARE)
Underwriting Agreement • January 15th, 2004 • GTX Inc/Tn • Pharmaceutical preparations • New York
COMMON STOCK PURCHASE WARRANT ONCTERNAL THERAPEUTICS, INC.
Oncternal Therapeutics, Inc. • July 21st, 2020 • Pharmaceutical preparations

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on January 21, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • July 21st, 2020 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of July 17, 2020, between Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

GTx, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF
Common Stock Warrant Agreement • May 12th, 2014 • GTX Inc /De/ • Pharmaceutical preparations • New York

This COMMON STOCK WARRANT AGREEMENT (this “Agreement”) is dated as of between GTx, Inc., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).

OPEN MARKET SALE AGREEMENTSM
Oncternal Therapeutics, Inc. • December 17th, 2021 • Pharmaceutical preparations • New York
GTx, INC. and ________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF ________
Preferred Stock Warrant Agreement • December 26th, 2007 • GTX Inc /De/ • Pharmaceutical preparations • New York

Preferred Stock Warrant Agreement (this “Agreement”), dated as of between GTx, Inc., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).

SUBLEASE
Sublease • July 27th, 2005 • GTX Inc /De/ • Pharmaceutical preparations • Tennessee
GTx, INC. and ________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF ________
Securities Warrant Agreement • December 26th, 2007 • GTX Inc /De/ • Pharmaceutical preparations • New York

Debt Securities Warrant Agreement (this “Agreement”), dated as of between GTx, Inc., a Delaware corporation (the “Company”) and ________, a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).

RECITALS
Indemnification Agreement • December 22nd, 2003 • GTX Inc/Tn • Pharmaceutical preparations • Delaware
16,666,667 Shares ONCTERNAL THERAPEUTICS, INC. Common Stock AMENDED AND RESTATED UNDERWRITING AGREEMENT
Underwriting Agreement • December 11th, 2020 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • New York

Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of 16,666,667 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”). The respective amount of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 2,495,000 shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.” This Amended and Restated Underwriting Agreement amends, restates and

GTX, INC. Common Stock ($0.001 par value per share) AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT
Terms Agreement • February 9th, 2018 • GTX Inc /De/ • Pharmaceutical preparations • New York

GTx, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through Stifel, Nicolaus & Company, Incorporated (“Stifel Nicolaus”), as sales agent and/or principal (“Agent”), shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), having an aggregate offering price of up to $50,000,000.00 on the terms set forth in Section 2 of this At-The-Market Equity Offering Sales Agreement (the “Agreement”). The Company agrees that whenever it determines to sell Shares directly to the Agent as principal, it will enter into a separate agreement (each, a “Terms Agreement”) in substantially the form of Annex I hereto, relating to such sale in accordance with Section 3 of this Agreement.

INDEMNIFICATION AGREEMENT
Indemnification Agreement • March 16th, 2020 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • Delaware

This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”), and , [a member of the Board of Directors/ an officer] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnification and advancement.

AutoNDA by SimpleDocs
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among:
Agreement and Plan of Merger and Reorganization • March 7th, 2019 • GTX Inc /De/ • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of March 6, 2019, by and among GTx, Inc., a Delaware corporation (“Parent”) Grizzly Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • September 29th, 2017 • GTX Inc /De/ • Pharmaceutical preparations • Delaware

This Securities Purchase Agreement (this “Agreement”) is dated as of September 25, 2017, between GTx, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Exhibit A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

GTX, INC.
Exclusive License Agreement • October 15th, 2003 • GTX Inc/Tn • Tennessee
Contract
GTX Inc /De/ • March 12th, 2014 • Pharmaceutical preparations • Delaware

NEITHER THIS WARRANT, NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT (COLLECTIVELY, THE “SECURITIES”), HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES OR BLUE SKY LAWS, PURSUANT TO REGISTRATION OR QUALIFICATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES OR BLUE SKY LAWS. THIS WARRANT IS SUBJECT TO THE TRANSFER RESTR

EMPLOYMENT AGREEMENT
Employment Agreement • March 24th, 2017 • GTX Inc /De/ • Pharmaceutical preparations • Tennessee

This Employment Agreement (this “Agreement”) is made and entered into as of January 6, 2017 (the “Effective Date”) by and between GTx, Inc., located at 175 Toyota Plaza, 7th Floor, Memphis, Tennessee 38103 (the “Employer”), and JASON SHACKELFORD (the “Employee”), residing at 2188 Wentworth Lane, Germantown, Tennessee 38139.

AMENDED AND RESTATED EMPLOYMENT AGREEMENT
Employment Agreement • March 3rd, 2009 • GTX Inc /De/ • Pharmaceutical preparations • Tennessee

This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into as of November 10, 2008 (the “Effective Date”) by and between GTx, Inc., located at 3 North Dunlap, 3rd Floor, Memphis, Tennessee 38163 (the “Employer”), and RONALD ALVIN MORTON, Jr., M.D. (the “Employee”), residing at 1588 Kirby Parkway, Memphis, Tennessee 38120.

STRICTLY CONFIDENTIAL Oncternal Therapeutics, Inc. 12230 El Camino Real Suite 300 San Diego, California 92130 Attn: James B. Breitmeyer, M.D., Ph.D., President and Chief Executive Officer
Letter Agreement • March 12th, 2021 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • New York

This letter agreement (this “Agreement”) constitutes the agreement between Oncternal Therapeutics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (the “Securities”) during the Term (as hereinafter defined) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwr

AMENDED AND RESTATED EMPLOYMENT AGREEMENT
Employment Agreement • August 5th, 2021 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • California

THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”), and Raj Krishnan, Ph.D. (“Executive”), and shall be effective as of January 6, 2021 (the “Effective Date”).

VOTING AGREEMENT
Voting Agreement • March 7th, 2019 • GTX Inc /De/ • Pharmaceutical preparations • Delaware

This VOTING AGREEMENT (this “Agreement”) is entered into as of March , 2019, among GTX, Inc., a Delaware corporation (“Parent”), Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”) and the undersigned (the “Stockholder”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • March 12th, 2014 • GTX Inc /De/ • Pharmaceutical preparations • Delaware

This Securities Purchase Agreement (this “Agreement”) is dated as of March 3, 2014, between GTx, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Exhibit A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

ONCTERNAL THERAPEUTICS, INC. RESTRICTED STOCK PURCHASE AGREEMENT
Restricted Stock Purchase Agreement • April 8th, 2019 • GTX Inc /De/ • Pharmaceutical preparations • California

THIS RESTRICTED STOCK PURCHASE AGREEMENT (“Agreement”) is made as of December 14, 2017, by and between ONCTERNAL THERAPEUTICS, INC., a Delaware corporation (the “Company”) and Richard G. Vincent (the “Purchaser”).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!